Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Isabl
AddedFeb 16, 2024
UpdatedJun 18, 2026
Isabl

Isabl

Isabl offers comprehensive cancer diagnostics using whole-genome analysis for precise treatment planning.

HQ
New York City, NY, US
Founded
2020
Accelerator
Y Combinator logoY CombinatorW20
Overview
Compare
Fundraising
Employees
Website

Founded with the mission to revolutionize cancer diagnostics, Isabl offers comprehensive whole-genome and transcriptome analysis to provide precise treatment planning. By leveraging advanced software, Isabl enables the analysis of entire tumor genomes, surpassing traditional methods that only examine a few mutations. This breakthrough technology provides unprecedented clarity into tumor biology, opening new opportunities for precision diagnosis and personalized cancer treatment.

Notable figures in the company include key scientists and technologists who have contributed to the development of their innovative software. Isabl has attracted significant interest from investors focused on healthcare and biotechnology advancements. Their key achievements include successful implementation of their technology in clinical settings, leading to more accurate and effective cancer treatment plans. Overall, Isabl's impact lies in its potential to transform cancer diagnostics and improve patient outcomes through precision medicine.

Isabl - Similar Companies

Epinoma logo

Epinoma

epinoma.com

Digistain logo

Digistain

digistain.co.uk

Nest Genomics logo

Nest Genomics

nestgenomics.com

MyCancerDB logo

MyCancerDB

ennov1.com

Data Driven Bioscience logo

Data Driven Bioscience

Oncobox logo

Oncobox

oncobox.com

GenomOncology logo

GenomOncology

genomoncology.com

BloodQ logo

BloodQ

bloodq.com

Genome Insight logo

Genome Insight

Variantyx logo

Variantyx

variantyx.com

Endpoint Health logo

Endpoint Health

Probably Genetic logo

Probably Genetic

Foundation Medicine logo

Foundation Medicine

Clear Gene logo

Clear Gene

cleargene.com

Yemaachi Biotechnology logo

Yemaachi Biotechnology

yemaachi.com

Isabl - Quick Facts

Who are Isabl's competitors?

Companies similar to Isabl include Epinoma, Digistain, Nest Genomics and MyCancerDB.

When was Isabl founded?

Isabl was founded in 2020.

Where is Isabl's headquarters located?

Isabl's headquarters is located in New York City, NY, US.

When was Isabl's last funding round?

Isabl's most recent funding round was for $2M (USD) in April 2023.

How much has Isabl raised to-date?

As of Apr 1, 2023, Isabl has raised a total of $5M (USD).

How many employees does Isabl have?

Isabl has 9 employees as of Feb 5, 2024.

Isabl - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Analytics
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cancer Diagnostics
Tags
  • Biotech
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8730Research, Development, And Testing Services
  • 8731Commercial Physical and Biological Research
Show 5 more industry codes
NAICS
  • 620000Health Care and Social Assistance
  • 623000Nursing and Residential Care Facilities
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified